User login
A shutdown, a lawsuit, and drug prices
As I write this editorial, regarding maintenance of certification. Being a doctor, these days, is neither easy nor relaxing.
The government shutdown is cheered by some, but it has real consequences for 800,000 government workers who are not getting paid, and our scientific community, where grant applications, hiring, data collection, and other critical roles of government are needed, is at a standstill. The class action suit against ABIM is the latest action of physicians telling the ABIM that enough is enough. Read more and form your opinion from our page one article. The ACA continues to be attacked in a variety of ways. To those who want to abolish it, please have a reasonable alternative in place so that real people with real diseases are not left in a desperate situation.
Drug prices continue to make news. The most recent example is the enormous increase in the cost of insulin. I read a lot about the inner workings of the pharmaceutical industry and cannot fathom how such prices are justified. Perhaps we physicians and our medical societies should consider raising our voices for our patients.
In this month’s issue there are several articles about polyp detection and the long-term protective effect of colonoscopy. We are doing really important and excellent work to reduce the burden of colon cancer.
As a heads up, Digestive Disease Week® (DDW) returns to San Diego this year. Housing choices are opening up and in San Diego fill rapidly; visit www.DDW.org/registration for more information. This year’s science is ground-breaking and will continue to advance our knowledge about IBD, the microbiome, and other important topics.
John I. Allen, MD, MBA, AGAF
Editor in Chief
As I write this editorial, regarding maintenance of certification. Being a doctor, these days, is neither easy nor relaxing.
The government shutdown is cheered by some, but it has real consequences for 800,000 government workers who are not getting paid, and our scientific community, where grant applications, hiring, data collection, and other critical roles of government are needed, is at a standstill. The class action suit against ABIM is the latest action of physicians telling the ABIM that enough is enough. Read more and form your opinion from our page one article. The ACA continues to be attacked in a variety of ways. To those who want to abolish it, please have a reasonable alternative in place so that real people with real diseases are not left in a desperate situation.
Drug prices continue to make news. The most recent example is the enormous increase in the cost of insulin. I read a lot about the inner workings of the pharmaceutical industry and cannot fathom how such prices are justified. Perhaps we physicians and our medical societies should consider raising our voices for our patients.
In this month’s issue there are several articles about polyp detection and the long-term protective effect of colonoscopy. We are doing really important and excellent work to reduce the burden of colon cancer.
As a heads up, Digestive Disease Week® (DDW) returns to San Diego this year. Housing choices are opening up and in San Diego fill rapidly; visit www.DDW.org/registration for more information. This year’s science is ground-breaking and will continue to advance our knowledge about IBD, the microbiome, and other important topics.
John I. Allen, MD, MBA, AGAF
Editor in Chief
As I write this editorial, regarding maintenance of certification. Being a doctor, these days, is neither easy nor relaxing.
The government shutdown is cheered by some, but it has real consequences for 800,000 government workers who are not getting paid, and our scientific community, where grant applications, hiring, data collection, and other critical roles of government are needed, is at a standstill. The class action suit against ABIM is the latest action of physicians telling the ABIM that enough is enough. Read more and form your opinion from our page one article. The ACA continues to be attacked in a variety of ways. To those who want to abolish it, please have a reasonable alternative in place so that real people with real diseases are not left in a desperate situation.
Drug prices continue to make news. The most recent example is the enormous increase in the cost of insulin. I read a lot about the inner workings of the pharmaceutical industry and cannot fathom how such prices are justified. Perhaps we physicians and our medical societies should consider raising our voices for our patients.
In this month’s issue there are several articles about polyp detection and the long-term protective effect of colonoscopy. We are doing really important and excellent work to reduce the burden of colon cancer.
As a heads up, Digestive Disease Week® (DDW) returns to San Diego this year. Housing choices are opening up and in San Diego fill rapidly; visit www.DDW.org/registration for more information. This year’s science is ground-breaking and will continue to advance our knowledge about IBD, the microbiome, and other important topics.
John I. Allen, MD, MBA, AGAF
Editor in Chief
Have you paid your 2019 SVS membership dues yet?
To those members who have not yet paid their 2019 dues -- are you planning to attend the Vascular Annual Meeting? Do you find your Journal of Vascular Surgery publications invaluable? Those are just two of the member benefits that will be lost to those who do not pay their dues soon. Others include use of trademarked professional designations and access to the new online communications forum, SVSConnect. Renew today to continue to receive these and all other SVS member benefits.
To those members who have not yet paid their 2019 dues -- are you planning to attend the Vascular Annual Meeting? Do you find your Journal of Vascular Surgery publications invaluable? Those are just two of the member benefits that will be lost to those who do not pay their dues soon. Others include use of trademarked professional designations and access to the new online communications forum, SVSConnect. Renew today to continue to receive these and all other SVS member benefits.
To those members who have not yet paid their 2019 dues -- are you planning to attend the Vascular Annual Meeting? Do you find your Journal of Vascular Surgery publications invaluable? Those are just two of the member benefits that will be lost to those who do not pay their dues soon. Others include use of trademarked professional designations and access to the new online communications forum, SVSConnect. Renew today to continue to receive these and all other SVS member benefits.
Women’s Leadership Training Grant
Because leadership skills are integral to success but are not typically taught in medical school, the SVS Leadership Development and Diversity Committee offers the Women's Leadership Training Grant to help women sharpen their leadership skills. The $5,000 awards (offered at three levels of a woman's career) defray costs to attend leadership courses and activities. Applications are due March 1.
Because leadership skills are integral to success but are not typically taught in medical school, the SVS Leadership Development and Diversity Committee offers the Women's Leadership Training Grant to help women sharpen their leadership skills. The $5,000 awards (offered at three levels of a woman's career) defray costs to attend leadership courses and activities. Applications are due March 1.
Because leadership skills are integral to success but are not typically taught in medical school, the SVS Leadership Development and Diversity Committee offers the Women's Leadership Training Grant to help women sharpen their leadership skills. The $5,000 awards (offered at three levels of a woman's career) defray costs to attend leadership courses and activities. Applications are due March 1.
Join the Conversation on SVSConnect
Transitioning toward retirement or looking for postgrad training opportunities? Or maybe you need some advice on good “power meals” to have during your busy days? These are only a few of the many threads attracting comments on SVSConnect, your online community. Members can discuss, collaborate, network and even share documents with one another. Log in with your SVS credentials and add your thoughts. If you’re not signed up, do so today.
Transitioning toward retirement or looking for postgrad training opportunities? Or maybe you need some advice on good “power meals” to have during your busy days? These are only a few of the many threads attracting comments on SVSConnect, your online community. Members can discuss, collaborate, network and even share documents with one another. Log in with your SVS credentials and add your thoughts. If you’re not signed up, do so today.
Transitioning toward retirement or looking for postgrad training opportunities? Or maybe you need some advice on good “power meals” to have during your busy days? These are only a few of the many threads attracting comments on SVSConnect, your online community. Members can discuss, collaborate, network and even share documents with one another. Log in with your SVS credentials and add your thoughts. If you’re not signed up, do so today.
Guideline public comment period framework
AGA is dedicated to integrity and transparency in the development of clinical guidance.
W In addition, to keep academic integrity of the AGA guideline, clinical practice update, and clinical pathway process, AGA follows the framework outlined by the Council of Medical Specialty Societies (CMSS) in The Code for Interaction with Companies.
The Code for Interaction with Companies states:
“7.15. Societies will not permit Guideline development panel members or staff to discuss a Guideline’s development with Company employees or representatives, will not accept unpublished data from Companies, and will not permit Companies to review Guidelines in draft form, except if a Society permits public or member comment on draft Guidelines as a part of the Society’s published Guideline development process.”
The Clinical Guidelines Committee and Clinical Practice Updates Committee strive to keep AGA’s clinical practice tools independent of industry influence and remain solely based on scientific evidence. As a result of this effort, AGA’s writing panels and chairs will have no direct communication with industry. Companies will have the opportunity to submit feedback during the public comment period. The panel will review any comments submitted through the online platform along with feedback from the public. The writing panel will take these suggestions into consideration when making revisions following the public comment period.
AGA is dedicated to integrity and transparency in the development of clinical guidance.
W In addition, to keep academic integrity of the AGA guideline, clinical practice update, and clinical pathway process, AGA follows the framework outlined by the Council of Medical Specialty Societies (CMSS) in The Code for Interaction with Companies.
The Code for Interaction with Companies states:
“7.15. Societies will not permit Guideline development panel members or staff to discuss a Guideline’s development with Company employees or representatives, will not accept unpublished data from Companies, and will not permit Companies to review Guidelines in draft form, except if a Society permits public or member comment on draft Guidelines as a part of the Society’s published Guideline development process.”
The Clinical Guidelines Committee and Clinical Practice Updates Committee strive to keep AGA’s clinical practice tools independent of industry influence and remain solely based on scientific evidence. As a result of this effort, AGA’s writing panels and chairs will have no direct communication with industry. Companies will have the opportunity to submit feedback during the public comment period. The panel will review any comments submitted through the online platform along with feedback from the public. The writing panel will take these suggestions into consideration when making revisions following the public comment period.
AGA is dedicated to integrity and transparency in the development of clinical guidance.
W In addition, to keep academic integrity of the AGA guideline, clinical practice update, and clinical pathway process, AGA follows the framework outlined by the Council of Medical Specialty Societies (CMSS) in The Code for Interaction with Companies.
The Code for Interaction with Companies states:
“7.15. Societies will not permit Guideline development panel members or staff to discuss a Guideline’s development with Company employees or representatives, will not accept unpublished data from Companies, and will not permit Companies to review Guidelines in draft form, except if a Society permits public or member comment on draft Guidelines as a part of the Society’s published Guideline development process.”
The Clinical Guidelines Committee and Clinical Practice Updates Committee strive to keep AGA’s clinical practice tools independent of industry influence and remain solely based on scientific evidence. As a result of this effort, AGA’s writing panels and chairs will have no direct communication with industry. Companies will have the opportunity to submit feedback during the public comment period. The panel will review any comments submitted through the online platform along with feedback from the public. The writing panel will take these suggestions into consideration when making revisions following the public comment period.
2018 AGA legislative wins
To those who took time to advocate on behalf of your profession and patients, thank you. Because of your efforts, we achieved several key successes that benefit clinicians, researchers and patients.
Together we were able to help advance several AGA policy priorities — administrative burden relief, digestive disease research and funding, and patient access and protection — as well as the science and practice of gastroenterology.
This year, we will be counting on you, our members, to again lead the charge to achieve AGA’s mission — empowering clinicians and researchers to improve digestive health — by calling on legislators and regulators to ensure the voice of gastroenterology continue to be heard.
NIH funding increase
AGA advocated and secured a $2 billion increase in NIH funding for fiscal year (FY) 2019. When added to increases from the two previous fiscal years, NIH’s funding has increased by 30 percent over the past three years, which is the largest increase since the doubling period in the last decade.
IPAB repeal prevents automatic Medicare cuts
Congress repealed the Independent Payment Advisory Board (IPAB) that was created as part of the Affordable Care Act (ACA). AGA and all of organized medicine long opposed IPAB since its sole purpose was to make budgetary cuts to Medicare if it reached a certain threshold of spending.
MIPS changes means more flexibility for physicians
AGA and the physician community were successful in securing flexibility under the new Medicare Quality Payment Program and the Merit-based Incentive Payment System (MIPS) that were created under the Medicare Access and CHIP Reauthorization Act. The changes give CMS more flexibility in implementing the program and will ensure that physicians have an opportunity to be successful in MIPS.
500 AGA members prevent radical changes to outpatient documentation
In response to a CMS proposal to radically change how outpatient evaluation and management (E/M) services are documented, more than 500 AGA members urged CMS not to move forward with its plan. As a result, CMS withdrew or delayed many of the proposed changes to E/M services that negatively impacted reimbursement. CMS did move forward with several changes to E/M documentation in an effort to reduce administrative burden.
AGA members send more than 940 letters to Congress
AGA launched the Congressional Advocates Program to provide an infrastructure and tools for members to effectively advocate on behalf of their profession and patients. AGA members heeded our calls to action and sent more than 940 letters sent to Congress and federal agencies throughout 2018. We thank our advocates whose participation makes a difference.
To those who took time to advocate on behalf of your profession and patients, thank you. Because of your efforts, we achieved several key successes that benefit clinicians, researchers and patients.
Together we were able to help advance several AGA policy priorities — administrative burden relief, digestive disease research and funding, and patient access and protection — as well as the science and practice of gastroenterology.
This year, we will be counting on you, our members, to again lead the charge to achieve AGA’s mission — empowering clinicians and researchers to improve digestive health — by calling on legislators and regulators to ensure the voice of gastroenterology continue to be heard.
NIH funding increase
AGA advocated and secured a $2 billion increase in NIH funding for fiscal year (FY) 2019. When added to increases from the two previous fiscal years, NIH’s funding has increased by 30 percent over the past three years, which is the largest increase since the doubling period in the last decade.
IPAB repeal prevents automatic Medicare cuts
Congress repealed the Independent Payment Advisory Board (IPAB) that was created as part of the Affordable Care Act (ACA). AGA and all of organized medicine long opposed IPAB since its sole purpose was to make budgetary cuts to Medicare if it reached a certain threshold of spending.
MIPS changes means more flexibility for physicians
AGA and the physician community were successful in securing flexibility under the new Medicare Quality Payment Program and the Merit-based Incentive Payment System (MIPS) that were created under the Medicare Access and CHIP Reauthorization Act. The changes give CMS more flexibility in implementing the program and will ensure that physicians have an opportunity to be successful in MIPS.
500 AGA members prevent radical changes to outpatient documentation
In response to a CMS proposal to radically change how outpatient evaluation and management (E/M) services are documented, more than 500 AGA members urged CMS not to move forward with its plan. As a result, CMS withdrew or delayed many of the proposed changes to E/M services that negatively impacted reimbursement. CMS did move forward with several changes to E/M documentation in an effort to reduce administrative burden.
AGA members send more than 940 letters to Congress
AGA launched the Congressional Advocates Program to provide an infrastructure and tools for members to effectively advocate on behalf of their profession and patients. AGA members heeded our calls to action and sent more than 940 letters sent to Congress and federal agencies throughout 2018. We thank our advocates whose participation makes a difference.
To those who took time to advocate on behalf of your profession and patients, thank you. Because of your efforts, we achieved several key successes that benefit clinicians, researchers and patients.
Together we were able to help advance several AGA policy priorities — administrative burden relief, digestive disease research and funding, and patient access and protection — as well as the science and practice of gastroenterology.
This year, we will be counting on you, our members, to again lead the charge to achieve AGA’s mission — empowering clinicians and researchers to improve digestive health — by calling on legislators and regulators to ensure the voice of gastroenterology continue to be heard.
NIH funding increase
AGA advocated and secured a $2 billion increase in NIH funding for fiscal year (FY) 2019. When added to increases from the two previous fiscal years, NIH’s funding has increased by 30 percent over the past three years, which is the largest increase since the doubling period in the last decade.
IPAB repeal prevents automatic Medicare cuts
Congress repealed the Independent Payment Advisory Board (IPAB) that was created as part of the Affordable Care Act (ACA). AGA and all of organized medicine long opposed IPAB since its sole purpose was to make budgetary cuts to Medicare if it reached a certain threshold of spending.
MIPS changes means more flexibility for physicians
AGA and the physician community were successful in securing flexibility under the new Medicare Quality Payment Program and the Merit-based Incentive Payment System (MIPS) that were created under the Medicare Access and CHIP Reauthorization Act. The changes give CMS more flexibility in implementing the program and will ensure that physicians have an opportunity to be successful in MIPS.
500 AGA members prevent radical changes to outpatient documentation
In response to a CMS proposal to radically change how outpatient evaluation and management (E/M) services are documented, more than 500 AGA members urged CMS not to move forward with its plan. As a result, CMS withdrew or delayed many of the proposed changes to E/M services that negatively impacted reimbursement. CMS did move forward with several changes to E/M documentation in an effort to reduce administrative burden.
AGA members send more than 940 letters to Congress
AGA launched the Congressional Advocates Program to provide an infrastructure and tools for members to effectively advocate on behalf of their profession and patients. AGA members heeded our calls to action and sent more than 940 letters sent to Congress and federal agencies throughout 2018. We thank our advocates whose participation makes a difference.
Help spark scientific breakthroughs with the AGA Research Foundation
The way we diagnose and treat patients is the result of years of research. But securing the future of the field is no small task. A donation to the charitable arm of the American Gastroenterological Association (AGA), the AGA Research Foundation, will help fill the funding gap and contribute to this tradition of discovery.
The foundation provides a key source of funding at a critical juncture in a young investigator’s career.
Help spark the scientific breakthroughs of today, so clinicians will have the tools to improve care tomorrow. Your tax-deductible donation will make a critical difference in retaining talented GI scientists, like Won Jae Huh, MD, whose research will impact the future care of patients.
“As a clinical researcher, funding for investigation is critical in scientific breakthroughs to promote more efficient and robust patient care. My project will provide novel insights into the role of distensibility in the treatment of patients with esophageal eosinophilia, potentially resulting in more efficient treatment selection and disease management.”
“This funding mechanism will secure my research time to investigate signaling pathways involved in the pathogenesis of Ménétrier’s disease, and will provide resources and support to launch my research career. The results from my research project will be helpful for treating Ménétrier’s disease patients.”
Help spark the scientific breakthroughs of today, so clinicians will have the tools to improve care tomorrow. Your tax-deductible donation will make a critical difference in retaining talented GI scientists, like Dr. Won Jae Huh, whose research will impact the future care of patients.
Donate on the foundation’s website at www.gastro.org/donateonline or by mail to 4930 Del Ray Avenue, Bethesda, MD 20814.
The way we diagnose and treat patients is the result of years of research. But securing the future of the field is no small task. A donation to the charitable arm of the American Gastroenterological Association (AGA), the AGA Research Foundation, will help fill the funding gap and contribute to this tradition of discovery.
The foundation provides a key source of funding at a critical juncture in a young investigator’s career.
Help spark the scientific breakthroughs of today, so clinicians will have the tools to improve care tomorrow. Your tax-deductible donation will make a critical difference in retaining talented GI scientists, like Won Jae Huh, MD, whose research will impact the future care of patients.
“As a clinical researcher, funding for investigation is critical in scientific breakthroughs to promote more efficient and robust patient care. My project will provide novel insights into the role of distensibility in the treatment of patients with esophageal eosinophilia, potentially resulting in more efficient treatment selection and disease management.”
“This funding mechanism will secure my research time to investigate signaling pathways involved in the pathogenesis of Ménétrier’s disease, and will provide resources and support to launch my research career. The results from my research project will be helpful for treating Ménétrier’s disease patients.”
Help spark the scientific breakthroughs of today, so clinicians will have the tools to improve care tomorrow. Your tax-deductible donation will make a critical difference in retaining talented GI scientists, like Dr. Won Jae Huh, whose research will impact the future care of patients.
Donate on the foundation’s website at www.gastro.org/donateonline or by mail to 4930 Del Ray Avenue, Bethesda, MD 20814.
The way we diagnose and treat patients is the result of years of research. But securing the future of the field is no small task. A donation to the charitable arm of the American Gastroenterological Association (AGA), the AGA Research Foundation, will help fill the funding gap and contribute to this tradition of discovery.
The foundation provides a key source of funding at a critical juncture in a young investigator’s career.
Help spark the scientific breakthroughs of today, so clinicians will have the tools to improve care tomorrow. Your tax-deductible donation will make a critical difference in retaining talented GI scientists, like Won Jae Huh, MD, whose research will impact the future care of patients.
“As a clinical researcher, funding for investigation is critical in scientific breakthroughs to promote more efficient and robust patient care. My project will provide novel insights into the role of distensibility in the treatment of patients with esophageal eosinophilia, potentially resulting in more efficient treatment selection and disease management.”
“This funding mechanism will secure my research time to investigate signaling pathways involved in the pathogenesis of Ménétrier’s disease, and will provide resources and support to launch my research career. The results from my research project will be helpful for treating Ménétrier’s disease patients.”
Help spark the scientific breakthroughs of today, so clinicians will have the tools to improve care tomorrow. Your tax-deductible donation will make a critical difference in retaining talented GI scientists, like Dr. Won Jae Huh, whose research will impact the future care of patients.
Donate on the foundation’s website at www.gastro.org/donateonline or by mail to 4930 Del Ray Avenue, Bethesda, MD 20814.
This month in the journal CHEST®
Editor’s Picks
Giants in Chest Medicine – Atul C. Mehta, MBBS, FCCP
By Dr. J. K. Stoller
Screening Heroin Smokers Attending Community Drug Services for COPD.
By Dr. H. Burhan, et al.
The NHLBI LAM Registry: Prognostic Physiologic and Radiologic Biomarkers Emerge
From a 15-Year Prospective Longitudinal Analysis.
By Dr. N. Gupta, et al.
Indwelling Pleural Catheters in Hepatic Hydrothorax: A Single-Center Series of Outcomes and Complications.
By Dr. C. Kniese, et al.
Implications of the Revised Common Rule for Human Participant Research.
By Dr. E. G. DeRenzo, et al.
Editor’s Picks
Giants in Chest Medicine – Atul C. Mehta, MBBS, FCCP
By Dr. J. K. Stoller
Screening Heroin Smokers Attending Community Drug Services for COPD.
By Dr. H. Burhan, et al.
The NHLBI LAM Registry: Prognostic Physiologic and Radiologic Biomarkers Emerge
From a 15-Year Prospective Longitudinal Analysis.
By Dr. N. Gupta, et al.
Indwelling Pleural Catheters in Hepatic Hydrothorax: A Single-Center Series of Outcomes and Complications.
By Dr. C. Kniese, et al.
Implications of the Revised Common Rule for Human Participant Research.
By Dr. E. G. DeRenzo, et al.
Editor’s Picks
Giants in Chest Medicine – Atul C. Mehta, MBBS, FCCP
By Dr. J. K. Stoller
Screening Heroin Smokers Attending Community Drug Services for COPD.
By Dr. H. Burhan, et al.
The NHLBI LAM Registry: Prognostic Physiologic and Radiologic Biomarkers Emerge
From a 15-Year Prospective Longitudinal Analysis.
By Dr. N. Gupta, et al.
Indwelling Pleural Catheters in Hepatic Hydrothorax: A Single-Center Series of Outcomes and Complications.
By Dr. C. Kniese, et al.
Implications of the Revised Common Rule for Human Participant Research.
By Dr. E. G. DeRenzo, et al.
Participate in a Retirement Plan
"Tranche" dates -- for completing all the paperwork for the Kai-Zen retirement accelerator program offered through the SVS Affinity Program of expanded benefits -- have been set for 2019. The first dates are Jan. 28, March 11 and May 6. Generally, paperwork can take approximately 30 or more days, but someone who has already started could meet the Jan. 28 date. Kai-Zen combines financing and life insurance, with premiums jointly funded by lenders and the participant (or an employer). It can help members speed investment growth in their life insurance policies, using leverage that provides up to 60 percent more death benefit protection and 60 percent more supplemental retirement income. See a video of how Kai-Zen works here. For more information contact Mark Blocker at [email protected] or at 312-291-4472.
"Tranche" dates -- for completing all the paperwork for the Kai-Zen retirement accelerator program offered through the SVS Affinity Program of expanded benefits -- have been set for 2019. The first dates are Jan. 28, March 11 and May 6. Generally, paperwork can take approximately 30 or more days, but someone who has already started could meet the Jan. 28 date. Kai-Zen combines financing and life insurance, with premiums jointly funded by lenders and the participant (or an employer). It can help members speed investment growth in their life insurance policies, using leverage that provides up to 60 percent more death benefit protection and 60 percent more supplemental retirement income. See a video of how Kai-Zen works here. For more information contact Mark Blocker at [email protected] or at 312-291-4472.
"Tranche" dates -- for completing all the paperwork for the Kai-Zen retirement accelerator program offered through the SVS Affinity Program of expanded benefits -- have been set for 2019. The first dates are Jan. 28, March 11 and May 6. Generally, paperwork can take approximately 30 or more days, but someone who has already started could meet the Jan. 28 date. Kai-Zen combines financing and life insurance, with premiums jointly funded by lenders and the participant (or an employer). It can help members speed investment growth in their life insurance policies, using leverage that provides up to 60 percent more death benefit protection and 60 percent more supplemental retirement income. See a video of how Kai-Zen works here. For more information contact Mark Blocker at [email protected] or at 312-291-4472.
This month in the journal CHEST®Editor’s Picks
Giants in Chest Medicine
Emeritus Professor Peter D. Wagner, MD
By Dr. Tatum S. Simonson
State of the Journal Editorial
Spread the Word About CHEST in 2019: Innovations, Introductions,
and Farewells. By Dr. R. S. Irwin, et al.
Original Research
Meta-analysis of Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis. By Dr. D. Bedard, et al.
Surgical Disparities Among Patients With Stage I Lung Cancer in the National Lung
Screening Trial. By Dr. A. A. Balekian, et al.
Evidence-Based Medicine
Clinically Diagnosing Pertussis-Associated Cough in Adults and Children: CHEST Guideline and Expert Panel Report. By Dr. A. Moore, et al.
Adult Outpatients With Acute Cough Due to Suspected Pneumonia or Influenza: CHEST Guideline and Expert Panel Report. By Dr. A. T. Hill, et al.
Giants in Chest Medicine
Emeritus Professor Peter D. Wagner, MD
By Dr. Tatum S. Simonson
State of the Journal Editorial
Spread the Word About CHEST in 2019: Innovations, Introductions,
and Farewells. By Dr. R. S. Irwin, et al.
Original Research
Meta-analysis of Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis. By Dr. D. Bedard, et al.
Surgical Disparities Among Patients With Stage I Lung Cancer in the National Lung
Screening Trial. By Dr. A. A. Balekian, et al.
Evidence-Based Medicine
Clinically Diagnosing Pertussis-Associated Cough in Adults and Children: CHEST Guideline and Expert Panel Report. By Dr. A. Moore, et al.
Adult Outpatients With Acute Cough Due to Suspected Pneumonia or Influenza: CHEST Guideline and Expert Panel Report. By Dr. A. T. Hill, et al.
Giants in Chest Medicine
Emeritus Professor Peter D. Wagner, MD
By Dr. Tatum S. Simonson
State of the Journal Editorial
Spread the Word About CHEST in 2019: Innovations, Introductions,
and Farewells. By Dr. R. S. Irwin, et al.
Original Research
Meta-analysis of Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis. By Dr. D. Bedard, et al.
Surgical Disparities Among Patients With Stage I Lung Cancer in the National Lung
Screening Trial. By Dr. A. A. Balekian, et al.
Evidence-Based Medicine
Clinically Diagnosing Pertussis-Associated Cough in Adults and Children: CHEST Guideline and Expert Panel Report. By Dr. A. Moore, et al.
Adult Outpatients With Acute Cough Due to Suspected Pneumonia or Influenza: CHEST Guideline and Expert Panel Report. By Dr. A. T. Hill, et al.